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Statins for patients with  
nonalcoholic fatty liver? 
Although physicians often avoid prescribing statins 
for patients with nonalcoholic fatty liver, their use has 
been found to reduce cardiovascular morbidity and 
mortality—and to lower liver enzymes.
Practice changer
Treat patients with hyperlipidemia and pre-
sumed nonalcoholic fatty liver disease with 
atorvastatin to reduce the risk of cardiovascu-
lar events.1
StREngtH of REcoMMEnDation 
B: Based on a single prospective randomized 
controlled trial (RCT). 
Athyros VG, Tziomalos K, Gossios TD, et al. Safety and efficacy of long-
term statin treatment for cardiovascular events in patients with coro-
nary heart disease and abnormal liver tests in the Greek Atorvastatin 
and Coronary Heart Disease Evaluation (GREACE) Study: a post hoc 
analysis. Lancet. 2010; 376:1916-1922.
illustrative case
an obese 58-year-old man with type 2 dia-
betes comes to your office for follow-up. his 
low-density lipoprotein cholesterol (lDl-c) is 
130 mg/dl; triglycerides, 300 mg/dl; alanine 
transaminase (alT), 110 units/l; and aspartate 
transaminase (aST), 120 units/l. The patient’s 
work-up for chronic hepatitis B and c, auto-
immune hepatitis, hemochromatosis, and Wil-
son’s disease are negative, and you rule out 
alcohol misuse based on his medical history. 
an ultrasound of the patient’s liver reveals he-
patic steatosis, and you diagnose nonalcoholic 
fatty liver disease (naflD). Should you start 
him on a statin? 
Patients with central obesity, diabetes, hypertension, hyperlipidemia, and metabolic syndrome are at high risk 
of developing NAFLD.  These conditions have 
increased in prevalence, and NAFLD is now 
the most common cause of liver disease in the 
United States.2 In Western industrialized coun-
tries, approximately 30% of the general popu-
lation and 70% to 90% of patients with diabetes 
will develop NAFLD.3 Although most patients 
are asymptomatic, their liver enzymes are el-
evated. To diagnose NAFLD, it is necessary to 
rule out alcoholic hepatitis with a medical his-
tory, and viral hepatitis, hereditary hemochro-
matosis, Wilson’s disease, and autoimmune 
hepatitis with laboratory testing. Ultrasound 
reveals fat accumulation in the liver. 
treatment for nafLD  
has little evidence of benefit
Patients with NAFLD have a much higher 
mortality rate than that of the general pub-
lic, primarily because of cardiovascular dis-
ease.4-6 Increased physical activity and weight 
loss is the only therapy that has solid evidence 
of a benefit,7 although other treatments, such 
as insulin-sensitizing drugs (metformin or pi-
oglitazone), may be beneficial.8 Surprisingly, 
atorvastatin has been found to reduce amino-
transferase levels in patients with NAFLD,9,10 
but clinicians are often concerned about 
prescribing a statin for patients with elevated 
liver enzymes. In one study, 50% of primary 
care physicians said they would not prescribe 
statins for patients whose liver enzymes are 
1.5× the upper limit of normal (ULN).11
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study summary
Statins lower risk of cardiovascular 
morbidity and mortality 
The Greek Atorvastatin and Coronary Heart 
Disease Evaluation (GREACE) study was a 
randomized, prospective open-label, inten-
tion-to-treat trial involving 1600 patients. 
All had established coronary heart disease 
(CHD), were younger than 75 years, and 
had triglycerides <400 mg/dL and LDL-C 
>100 mg/dL. The study reviewed here—
evaluating the risk-to-benefit ratio of using 
a statin to treat hyperlipidemia in patients 
with NAFLD—was a post hoc analysis of the 
GREACE study.1 
Participants were randomized to either 
usual care or structured care with atorvas-
tatin, starting at 10 mg/d and adjusted to 
80 mg/d to bring the LDL-C level below 
100 mg/dL. In the usual care group, treat-
ment included lifestyle changes plus neces-
sary drug treatments (only 30% of those in 
the usual care group received hyperlipidemia 
drugs). Patients were followed after medica-
tion dose titration, then every 6 months for 
3 years. Serum ALT and AST were measured 
at baseline, at 6 weeks, and every 6 months. 
At baseline, mild-to-moderate increases 
(<3× ULN) in ALT/AST were noted in 437 of 
the 1600 patients. For these patients, alco-
holic hepatitis, chronic hepatitis B and C, 
Wilson’s disease, and autoimmune hepatitis 
were excluded by history, laboratory tests, 
and ultrasound, and the elevated liver en-
zymes were attributed to NAFLD. 
z the primary endpoints were the first 
occurrence of any cardiovascular event, 
including nonfatal myocardial infarction, 
revascularization, unstable angina, heart 
failure, and stroke; all-cause mortality; and 
CHD mortality. The relative risk (RR) for such 
events was calculated for the 437 patients 
with elevated liver enzymes, compared with 
that of patients without abnormal liver tests. 
Elevated liver enzymes and liver-related ad-
verse events were secondary endpoints. 
A cardiovascular event occurred in 10% 
(22/227) of the patients with elevated liver 
enzymes who received a statin, and 30% 
(63/210) of patients who had elevated liver 
enzymes but did not receive a statin. 
There were 3.2 events per 100 patient-
years in the atorvastatin group, compared 
with 10 events per 100 patient-years in those 
not on atorvastatin, a 68% reduction in RR 
(P<.0001) and an NNT of 15 per year to pre-
vent one cardiovascular event. The risk re-
duction in cardiovascular events was greater 
in patients with NAFLD (68%) than in pa-
tients with normal liver tests (39%). 
An added benefit was the reduction in 
ALT/AST levels during treatment for patients 
with NAFLD who were taking a statin, an av-
erage decrease of 47% in AST levels and 35% 
in ALT levels. In addition, 89% of the patients 
in the statin group had normal ALT, AST, and 
gamma-glutamyl transferase levels by the 
end of the 3-year follow-up. Patients with 
NAFLD who did not receive statins had a 12% 
increase in AST and ALT by the end of the 
3-year study. 
Only 10 of 880 patients taking statins de-
veloped liver enzymes more than 3× ULN. In 
3 of these patients, dose adjustments brought 
the liver enzymes back to normal. Only 
7 (<1%) patients who received a statin had to 
discontinue therapy because of liver-related 
adverse effects. 
What’s neW
Liver enzymes improve, 
with few adverse effects 
Preliminary studies have shown an improve-
ment in liver enzymes in patients with NAFLD 
treated with a statin.9,10 This is the first study 
to show survival benefits and significant re-
duction in major cardiovascular morbidity 
for such patients, as well. 
This is also the first large-scale study that 
shows that treating NAFLD patients with a 
statin decreases liver enzyme levels, with 
minimal adverse effects. 
caveats
Differences in groups, few women 
could skew results 
This study cannot be considered the final 
word on this topic. Patients in the “structured 
care” group were followed at a university 
clinic, while those in the “usual care” group 
were followed by either a family physician or 
a cardiologist outside the hospital, based on 
this is the first 
study to show 
survival benefits 
and significant 
reduction  
in major  
cardiovascular 
morbidity for 
patients with 
nafLD treated 
with a statin.
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their choice. There may have been other dif-
ferences in the care received by the 2 groups 
that could account for the difference in mor-
tality and morbidity reduction.
In addition, study participants had coro-
nary artery disease, and atorvastatin was not 
used for primary prevention. Moreover, near-
ly 80% of the study participants were male, 
which raises the question of generalizability. 
And this study was a post hoc analysis of the 
larger GREACE study, which also raises con-
cerns about the validity of findings. 
In the absence of a larger prospective RCT, 
however, this is the best available evidence 
to support the use of statins in this popula-
tion, and suggests that treating patients with 
NAFLD with statins is safe and effective.
challenges to imPlementation
Extensive Dx tests are costly 
Study participants were evaluated to rule out 
other causes of their abnormal liver tests, 
with extensive laboratory tests and an ul-
trasound evaluation of the liver. Such exten-
sive testing may be cost prohibitive in some 
situations.                  JFP
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